| 44th week of 2008 patent applcation highlights part 42 |
| Patent application number | Title | Published |
|---|
| 20080267841 | REAL-TIME IMAGING AND SPECTROSCOPY DURING MICROWAVE ASSISTED CHEMISTRY - An instrument and associated method are disclosed for conducting microwave assisted chemical reactions. The instrument includes a microwave cavity, preferably a closed microwave cavity, for conducting microwave assisted chemical reactions, and a source for applying microwave radiation within the cavity and to a vessel and its contents. The instrument also includes an illumination source for illuminating the vessel and its contents, as well as means for visually observing the vessel and its contents, an infrared detector for monitoring the temperature of the vessel and its contents, and means for preventing the illumination source from saturating the infrared detector, thereby enabling concurrent visual observation and infrared monitoring. | 2008-10-30 |
| 20080267842 | PROCESS AND APPARTUS FOR THE PRODUCTION OF USEFUL PRODUCTS FROM CARBONACEOUS FEEDSTOCK - A carbonaceous feedstock to alcohol conversion process in which carbon dioxide and a portion of the hydrogen produced are removed from the syngas stream issuing from a feedstock reformer, to yield a reduced hydrogen, carbon monoxide and methane syngas stream. The hydrogen and the carbon dioxide are passed through a Fischer Tropsch reactor which is catalyzed to favor the production of methanol. The methanol produced in the Fischer-Tropsch reactor is passed with the reduced hydrogen syngas through a second Fischer-Tropsch reactor which is catalyzed to favor the production of ethanol. Also disclosed, without limitation, are a unique catalyst, a method for controlling the content of the syngas formed in the feedstock reformer, and a feedstock handling system. | 2008-10-30 |
| 20080267843 | Spinning Disc Reactor with Spiral Passageway for Heat Transfer Fluid - There is disclosed a reactor apparatus including a support element that is rotatable about an axis and which has a first surface generally centered on the axis. The first surface is adapted for outward radial flow of a thin film of fluid phase reactant thereacross when supplied thereto as the support element is rotated. The support element also has a second surface opposed to the first surface and which is in thermal communication with the first surface. The second surface is provided with a spiral passageway generally centered on the axis and also with means for supplying a heat transfer fluid to the spiral passageway. By providing a spiral passageway for the heat transfer fluid, improved heat transfer from the first surface to the heat transfer fluid is obtained. | 2008-10-30 |
| 20080267844 | REACTOR HEATER - A heater for supplying heat to a plurality of detachable reactors is provided, the heater including a plurality of independent heating zones, each heating zone including: a hot-air heater; an output port adapted for connection to a heating cavity of a reactor; an exhaust port adapted for connection to the heating cavity of said reactor; and an air source arranged to cause air heated by said hot-air heater to pass through said output port and to return through said exhaust port when a reactor is attached to said output nozzle and said exhaust port. The heater can supply highly controllable heat to a plurality of different types of reactor while controlling the temperature of each individually. A kit containing a heater and a variety of reactors is also provided. | 2008-10-30 |
| 20080267845 | Multipurpose Flow Module - The present invention relates to a multipurpose flow module comprising flow plates and/or heat exchanger plates stacked together, which flow plate having a flow channel and one or more connection ports. To each flow plate or heat exchanger plate one or more barrier plates may be attached. The present invention further relates to a method for extraction, for reaction, for mixing, or combinations thereof in the multipurpose flow module, and to uses of the multipurpose flow module. | 2008-10-30 |
| 20080267846 | PROCESSES FOR THE PURIFICATION AND OXIDATION OF A HYDROGEN CHLORIDE-CONTAINING GAS WHICH ALSO CONTAINS SULFUR COMPOUND(S) - Processes comprising: providing a crude gas comprising hydrogen chloride and at least one sulfur compound; and passing the crude gas across a sacrificial material such that at least a portion of the at least one sulfur compound is oxidized and precipitated as sulfate onto the sacrificial material to provide a hydrogen chloride product gas. | 2008-10-30 |
| 20080267847 | PROCESS AND SYSTEM FOR REMOVING HYDROGEN SULFIDE AND MERCAPTANS IN AMMONIA-BASED DESULFURIZATION SYSTEMS - A flue gas desulfurization process and system that utilize ammonia as a reactant, and in which any hydrogen sulfide and/or mercaptans within the ammonia are separated during the desulfurization process so as to prevent their release into the atmosphere. The process and system entail absorbing acidic gases from a flue gas with a scrubbing media containing ammonium sulfate to produce a stream of scrubbed flue gas, collecting the scrubbing media containing the absorbed acidic gases, injecting into the collected scrubbing media a source of ammonia that is laden with hydrogen sulfide and/or mercaptans so that the injected ammonia is absorbed into and reacted with the collected scrubbing media, stripping the hydrogen sulfide and/or mercaptans from the collected scrubbing media by causing the hydrogen sulfide and/or mercaptans to exit the collected scrubbing media as stripped gases, and collecting the stripped gases without allowing the stripped gases to enter the stream of scrubbed flue gas. | 2008-10-30 |
| 20080267848 | Apparatus and Methods for Non-Regenerative and Regenerative Hot Gas Sulfurization - Disclosed is a doped cerium oxide sorbent that can effectively and regenerably remove H | 2008-10-30 |
| 20080267849 | PROCESSES FOR THE OXIDATION OF CARBON MONOXIDE IN A GAS STREAM CONTAINING HCL - Processes comprising: providing a gas stream comprising hydrogen chloride and carbon monoxide; and oxidizing at least a portion of the carbon monoxide in the gas stream in the presence of a catalyst to form a product gas comprising hydrogen chloride and carbon dioxide; wherein the catalyst comprises tin dioxide and a ruthenium compound comprising at least one element selected from the group consisting of oxygen and chlorine. | 2008-10-30 |
| 20080267850 | Method of producing phosphoric acid salt - A method of preparing a phosphoric acid salt which includes at least one attack on phosphate ore by an aqueous solution of hydrochloric acid, with the formation of an attack liquor, a first separation, in the attack liquor, between an insoluble solid phase and an aqueous phase, a neutralization of the separated aqueous phase by the addition of a calcium compound in order to form, with phosphate ions contained in this aqueous phase, a calcium phosphate insoluble in water, which precipitates, and a second separation, in the neutralized aqueous phase, between a liquid phase and a precipitated solid phase based on the calcium phosphate insoluble in water, wherein the attack on the phosphate ore includes dissolving the phosphate in the ore, the attack liquor containing this phosphate in the form of phosphate ions, and the solid phase separated from the attack liquor contains impurities and the aqueous phase separated from the attack liquor contains the phosphate ions thereof, chloride ions and calcium ions, this aqueous phase being subjected to the neutralization and second-separation steps. | 2008-10-30 |
| 20080267851 | High Whiteness Metakaolin and High Whiteness Fully Calcined Kaolin - The present invention relates to calcined kaolins having optimal whiteness and brightness properties. The calcined kaolins can comprise metakaolin, fully calcined kaolin, or flash calcined kaolin. The kaolin can be calcined from hydrous kaolin that has been subjected to enhanced magnetic separation. The resulting calcined kaolin can have a whiteness defined by a Hunter lab coordinate L value of at least about (96). The calcined kaolin can also have a brightness of at least about (90), as measured by a Technibrite TB-1C instrument. The present invention also relates to methods of preparing calcined kaolins. The present invention also relates to paints, polymers, coatings, ceramics, paper, and cementitious products comprising these calcined kaolins. | 2008-10-30 |
| 20080267852 | Process for Preparing Pulverulent Solids - Process for preparing pulverulent solids, in which one or more oxidizable and/or hydrolysable metal compounds are reacted in a high-temperature zone in the presence of oxygen and/or steam, the reaction mixture is cooled after the reaction, and the pulverulent solid is removed from gaseous substances, wherein at least one metal compound is introduced into the high-temperature zone in solid form and the evaporation temperature of the metal compound is below the temperature of the high-temperature zone. | 2008-10-30 |
| 20080267853 | PROCESS FOR PRODUCING INORGANIC SPHERES - To provide a process for producing inorganic spheres having a substantially uniform particle size with high productivity. In a process for producing inorganic spheres, which comprises a step of injecting an alkaline aqueous liquid containing an inorganic compound into a laminar flow of an organic liquid containing a surfactant through micropores to form a W/O type emulsion, and a step of solidifying droplets of the aqueous liquid containing an inorganic compound in the W/O type emulsion by an acid to form inorganic spheres, as the organic liquid, one which is brought into contact with an acid in a state of the W/O type emulsion or after separated from the W/O type emulsion, or one which is brought into contact with the aqueous liquid and then separated and recovered, is used. | 2008-10-30 |
| 20080267854 | Process for Producing Carbonate Particles - To provide a process for producing carbonate particles, capable of efficient, easy formation of carbonate particles which have high crystallinity, less prone to agglomeration and offer orientation birefringence, particularly carbonate particles that are needle- or rod-shaped, and of controlling the particle size. In the process a metal ion source and a carbonate ion source are heated together in a liquid of 55° C. or higher for reaction to produce carbonate particles with an aspect ratio of greater than 1, wherein the metal ion source contains at least one metal ion selected from the group consisting of Sr | 2008-10-30 |
| 20080267855 | PROCESS FOR THE PRODUCTION OF METAL FLUORIDE MATERIALS WITH SUBMICRON STRUCTURES - A process for the production of metal fluorides comprising maintaining a low concentration of the by-products of the reaction between a non-fluorinated metal compound and hydrofluoric acid, so as to produce, by this reaction, sub-micron particle sizes of metal fluoride of high purity. | 2008-10-30 |
| 20080267856 | Removal of contaminants from by-product acids - The present invention is drawn to a method for removing colloidal titanium dioxide and titanium oxychloride from by-product hydrochloric acid. The method includes adding phosphate ion source and quaternary amine to the by-product acid to cause the titanium dioxide and the titanium oxychloride to form a precipitate. The precipitate can then be separated from the acid, thus producing a decontaminated hydrochloric acid product with reduced levels of titanium. | 2008-10-30 |
| 20080267857 | RUTHENIUM CATALYSTS HAVING ENHANCED LONG-TERM STABILITY AND ACTIVITY - Oxidation catalysts comprising one or more ruthenium compounds and one or more promoters selected from the group consisting of zirconium halides, alkali metal halides, alkaline earth metal halides and lanthanum compounds, wherein the molar ratio of promoter to ruthenium is in the range of from 1:100 to 1:1; as well as processes for their preparation and use. | 2008-10-30 |
| 20080267858 | Reduced Moisture Chemical Reactions - A method of continuously producing reduced compounds, which comprises continuously feeding our oxidised compound into a reaction chamber and contracting the oxidised compound with a reductant gas. The oxidised compound may be titanium dioxide. the reaction chamber may be a rotating kiln. | 2008-10-30 |
| 20080267859 | CATALYTIC HYDROGEN PRODUCTION FROM HYDROLYTIC OXIDATION OF ORGANOSILANES - A novel application of a transition metal oxo complex, a cationic oxorhenium(V) oxazoline, in the production of molecular hydrogen (H | 2008-10-30 |
| 20080267860 | Crystalline Microporous Material Of Zeolitic Nature - A crystalline microporous material of zeolitic nature (ITQ-41) having in its calcined form a chemical composition represented by the empirical formula: | 2008-10-30 |
| 20080267861 | Myocardial Perfusion Imaging - This invention relates to methods for performing myocardial perfusion imaging for diagnosing and characterizing coronary artery disease using an intravenous (IV) bolus injection of regadenoson while the patient is undergoing sub-maximal exercise. | 2008-10-30 |
| 20080267862 | METHOD OF TREATING CANCER - Present invention provides a method for treating cancer which comprises co-administration of an angiogenic agent to enhance the vascular supply within tumors, particularly tumors capable of maintaining their viability under hypoxic conditions, and a anticancer therapy (e.g. chemotherapy and radiation therapy) to which the cancer is susceptible. Induction of angiogenesis increases the delivery of anticancer agents to the hypoxic tumor cells within the tumors, and as a result, improves the effectiveness of the anticancer therapy in eliminating or reducing cancers. The present invention also includes formulations comprising of lysine(L- and/or D-isomers as well as, or, their “activated” version either in isolation or in various combinations, as described, along with additive(s) and one or more chemotherapeutic agent(s) and/or radio-sensitizing agent(s). | 2008-10-30 |
| 20080267863 | Method of Diagnosing, Monitoring, Staging, Imaging and Treating Colon Cancer - The present invention provides new methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating colon cancer. | 2008-10-30 |
| 20080267864 | Cancerous disease modifying antibodies - The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. | 2008-10-30 |
| 20080267865 | Targeting of Erb Antigens - A conjugate comprising
| 2008-10-30 |
| 20080267866 | Novel Antiviral Macrocycle Derivatives and Metal Complexes, Incorporating Bridged Macrocycles - A compound of Formulae (1), (2) or (3), A | 2008-10-30 |
| 20080267867 | Metal Complexes of N-Heterocyclic Carbenes as Radiopharmaceuticals and Antibiotics - A method for inhibiting microbial growth comprises administering an effective amount of a silver complex of a N-heterocyclic amine. A method for treating cancer cells or a method for imaging one or more tissues of a patient includes administering an effective amount of a complex of a N-heterocyclic amine and a radioactive metal. N-heterocyclic carbenes of the present invention may be represented by formula (I) wherein Z is a heterocyclic group, and R | 2008-10-30 |
| 20080267868 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex - A process for diagnostic imaging of heart or adrenal glands of a human being comprises administering to the human being a radiopharmaceutical containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound and a bidentate ligand and represented by the formula (1): [ | 2008-10-30 |
| 20080267869 | RADIOACTIVE TRANSITION METAL-IMIDO HETERO-DIPHOSPHINE COMPLEXES, THEIR PREPARATION AND RADIOPHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides radioactive metal heterocomplexes of formula (I): [(Me=N—R)L | 2008-10-30 |
| 20080267870 | 1-[(2'-Substituted)-piperazin-1' -yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents - Racemic mixtures and enantiomerically pure forms of novel 1-[(2′-substituted)-piperazin-1′-yl]-isoquinolines are norepinephrine (NE) transporter (NET) inhibitor compounds. Compounds of the invention are considered therapeutic agents for central nervous system (CNS) diseases and disorders, without limitation, including neurodegeneration, anxiety, depression, attention deficit disorders, drug dependency, and post traumatic stress disorder. Examples of the chemical syntheses of the compounds of the invention are provided. The isoquinoline compounds of the invention competitively bind at NET at nanomolar concentrations. The isoquinoline agents of the invention bind selectively to NET over other competitive transporter targets and receptor binding sites, including those of serotonin and dopamine, amongst others. The chemical syntheses of the invention are suitable for labeling with radionuclide atoms. Radiolabeled forms of the novel 1-[(2′-substituted)-piperazin-1′-yl]-isoquinoline compounds are positron emission tomography and single photon emission tomography imaging tracers. Methods of in vivo imaging with the tracers within various subjects and tissues therein, including regions of the brain, are provided. Imaging methods with the tracers in combination other NET inhibitor agents are provided. The imaging methods within subjects allow quantitative detection of NET, determinations of NET distributions, and measures of tracer interactions at NET in the presence or absence of non-radioactive NET agents. The tracer imaging methods are suitable to locate, diagnose, identify, evaluate, detect or quantitate NET, or abnormalities of NET, or NE abnormalities; that are associated with various CNS diseases and disorders. | 2008-10-30 |
| 20080267871 | Cardioinhibitory/ Antihypertensive Novel Endogenous Physiologically Active Peptide - [Object] The present invention is to provide a novel peptide having a potent hypotensive activity by inhibiting cardiac contractility, a DNA encoding the peptide, an antibody against the peptide, or a cardioinhibitory/hypotensive agent comprising the peptide as an active ingredient. A search of a genetic data base revealed the presence of a peptide biosynthesized by a processing of unspliced product of TOR2A mRNA. As a result of functional analysis, a peptide hormone exerting a potent bioactivity and expressed abundantly throughout human organs was found. The peptide is hydrophobic with a molecular weight of 2664.02 consisting of 24 amino acids (AIFIFISNTGGKQINQVALEAWRS) and shows a negative inotropism in rat hearts, as well as a marked systemic hypotensive activity. | 2008-10-30 |
| 20080267872 | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer - A novel gene 098P4B6 (also designated STEAP-2) and its encoded protein, and variants thereof, are described wherein 98P4B6 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 98P4B6 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 98P4B6 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 98P4B6 can be used in active or passive immunization. | 2008-10-30 |
| 20080267873 | Injection Solution for Rna - The invention relates to the use of RNA and an aqueous injection buffer containing a sodium salt, a calcium salt and optionally a potassium salt and optionally lactate, in the preparation of a RNA injection solution for increasing RNA transfer and/or RNA translation into/in a host organism. The invention relates further to a RNA injection solution and to a method for increasing the RNA transfer and/or RNA translation of RNA in vivo and in vitro. | 2008-10-30 |
| 20080267874 | Targeted Neuronal And Glial Human Embryonic Stem Cell Line - The present invention is related to human stem cells lines comprising a targeted gene construct, and in particular to human embryonic stem cells lines (hESC) comprising a reporter gene inserted into the Olig2 locus via homologous recombination. The hESC line remains pluripotent and maintains a normal karyotype, and allows for visualization of Olig2 expression by fluorescence microscopy and sorting by FACS. Since Olig2 is important is the development of motor neurons and oligodendrocytes, the present invention provides a means to study differentiation of stem cells into motor neurons and oligodendrocytes, as well as the study of intrinsic and extrinsic factors that affect such differentiation. The hESCs of the present invention also provide a means to study and determine optimal factors and conditions for cell differentiation. | 2008-10-30 |
| 20080267875 | STEROID CONJUGATES, PREPARATION THEREOF AND THE USE THEREOF - Conjugates comprising one or more steroids conjugated with one or more mammalian proteins are disclosed. The conjugates are useful for diagnosis or treatment of solid cancer aid haematological malignancies. Further the conjugates exhibits a synergistic action together with a cytoskeleton acting drug such as Taxol®, which enable the treatment of cancers that otherwise would be non responsive to Taxol®. | 2008-10-30 |
| 20080267876 | Nanoparticles for Targeted Delivery of Active Agent - The present invention concerns a delivery system comprising a polymer-based nanoparticle; and a linker comprising a first portion non-covalently anchored to said nanoparticle, wherein at least part of said first portion comprises a hydrophobic/lipophilic segment embedded in said nanoparticle; and a second portion comprising a maleimide compound exposed at the outer surface of said nanoparticle. In accordance with one embodiment, the delivery system comprises one or more targeting agents, each covalently bound to said maleimide compound. In accordance with yet another embodiment, the delivery system comprises a drug. A specific example for a linker in accordance with the invention is octadecyl-4-(maleimideomethyl)cyclohexane-carboxylic amide (OMCCA). | 2008-10-30 |
| 20080267877 | Peptide-based carrier devices for stellate cells - A compound includes a carrier molecule wherein the carrier molecule is linked to a further molecule, wherein the further molecule is at least one cyclic peptide in which the cyclic peptide portion thereof contains at least one sequence encoding a cell receptor recognizing peptide (RRP) and with the proviso that the compound is not a naturally occurring receptor agonist or antagonist. Preferably, the RRP is a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is up-regulated on HSC during disease. The RFP may be chosen from among a PDGF receptor, a collagen type VI receptor, cytokine receptor(s) such as TGBβ, INFα and interleukinβ. The cyclic portion of the peptide can contain at least one amino acid sequence RGD or KPT. The compounds can be used as an active targeting ingredient for manufacturing a pharmaceutical composition for therapy, prophylaxis or diagnosis of a disease chosen from fibrotic disease, sclerotic disease, and chronic or acute inflammatory processes including glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, rheumatoid arthritis, Crohns disease, colitis ulcerosa, glomerulonephritis and sepsis, and particularly for targeting HSC. Pharmaceutical compositions contain the above-compound(s). | 2008-10-30 |
| 20080267878 | Targeted Imaging And/Or Therapy Using The [3+2] Azide-Alkyne Cycloaddition - The use of a selective chemical and bioorthogonal reaction providing a covalent ligation such as the [3+2] cycloaddition, in targeted molecular imaging and therapy is presented, more specifically with interesting applications for pre-targeted imaging or therapy. Current pre-targeted imaging is hampered by the fact that it relies solely on natural/biological targeting constructs (biotin/streptavidin). Size considerations and limitations associated with their endogenous nature severely limit the number of applications. The present invention describes how the use of an abiotic, bio-orthogonal reaction which forms a stable adduct under physiological conditions, by way of a small or undetectable bond, can overcome these limitations. | 2008-10-30 |
| 20080267879 | Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders - The present invention relates to compounds and methods for imaging and treating Alzheimer's disease or an amyloidosis-associated pathological condition that utilize a novel amyloid imaging tracer for detecting amyloid deposits in a subject suffering from these conditions. In certain embodiments, the invention relates to [N-2[18F]fluoropropyl]-2-(4′-(methylamino)-phenyl)-6-hydroxybenzothiazole (F-18MHT) and dimers thereof. | 2008-10-30 |
| 20080267880 | AUTOMATED METHOD FOR HIGH THROUGHTOUT SCREENING OF NEMATODES - This invention provides a high throughput survival assay, using uptake of a marker dye (e.g. a fluorescent dye) as a marker of death of a nematode. The assay permits high throughput screening of thousands of compounds possible. By the application of automated worm handling technology we are able to accurately dispense nematodes into 384 well microtitre plates, at rates many thousand of times faster than previously possible. In addition, we have automated the analysis of survival by the use of a fluorometric plate reader that quantitates the degree of fluorescence within each well. | 2008-10-30 |
| 20080267881 | IMAGING AGENTS - The invention relates to compounds of formula (I): and their use as targeting vectors that bind to receptors associated with angiogenesis. Such compounds may thus be used for diagnosis or therapy of, for example, malignant diseases, heart diseases, endometriosis, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma. | 2008-10-30 |
| 20080267882 | Imaging compounds, methods of making imaging compounds, methods of imaging, therapeutic compounds, methods of making therapeutic compounds, and methods of therapy - Embodiments of the present disclosure provide for RGD compounds that include a multimeric RGD (arginine-glycine-aspartic acid (Arg-Gly-Asp)) peptide, methods of making the RGD compound, pharmaceutical compositions including RGD compound, methods of using the RGD compositions or the pharmaceutical compositions including RGD compositions, methods of diagnosing and/or targeting angiogenesis related disease and related biological events, kits for diagnosing and/or targeting angiogenesis related disease and related biological events, and the like. In addition, the present disclosure includes compositions used in and methods relating to non-invasive imaging (e.g., positron emission tomography (PET) imaging) of the RGD compounds in vivo. | 2008-10-30 |
| 20080267883 | Nicotinic and Picolinic Acid Derived Near-Infrared Fluorophores - This invention relates to new fluorescent chemical entities, including fluorescent molecules that comprise a carboxyl or carbonyl functionalized pyridine moiety. This invention also relates to the corresponding reactive versions of such molecules. This invention also relates to the corresponding conjugates with moieties such as peptides, proteins, various biomolecules, carbocyclic and heterocyclic compounds, sugars, and their uses thereof. | 2008-10-30 |
| 20080267884 | Contrast Agents and Diagnostic Compositions Based on Iodine-Containing Cyanuric Acid Derivatives - The present invention relates to a class of compounds of Formula (I) and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing a cyanuric acid scaffolding moiety allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging and to contrast media containing such compounds. | 2008-10-30 |
| 20080267885 | Medicinal Compositions and Method for the Preparation Thereof - Methods for the manufacture of medicinal compositions are described. A method for the manufacture of a medicinal composition according to the invention comprises: (a) Providing a biocompatible polymer of the general formula —[O—R | 2008-10-30 |
| 20080267886 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists - A medicament comprising, separately or together (A) glycopyrrolate; and | 2008-10-30 |
| 20080267887 | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds - Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds analogues of the formula: | 2008-10-30 |
| 20080267888 | Heterocyclic Derivatives - The present invention relates to novel heterocyclic derivatives of the general formula (I), their pharmaceutically acceptable salts and compositions, their analogs, their tautomeric forms, and their stereoisomers. The present invention more particularly provides novel compounds of the general formula (I). | 2008-10-30 |
| 20080267889 | Cosmetic Cooling Composition - The invention relates to a cosmetic composition having a cooling effect, particularly a clear gel or a spray. The composition has a long-lasting cooling effect of about 8 hours and comprises a cooling complex consisting of 0.05-0.15% Menthyl Lactate, 0.1-0.2% Menthyl PCA and 0.05-0.2% Ethyl Menthane Carboxamide. | 2008-10-30 |
| 20080267890 | Anti-Microbial Agent - A composition comprising a C8 to C24 polyunsaturated fatty acid such as-linolenic or ester thereof, and terpinene-4-ol or derivative thereof. The composition has activity as a broad-spectrum antibacterial composition. | 2008-10-30 |
| 20080267891 | Oral Care Composition To Reduce Or Eliminate Dental Sensitivity - The invention includes an oral care composition that reduces and/or eliminates the perception of tooth sensitivity. The composition includes an adherent material and particles having an average particle size of about 8 microns or less. The particles are present in the composition in an amount of about 5% by weight. Also included within the scope of the invention are related methods, such as methods of occluding a dentin tubule. | 2008-10-30 |
| 20080267892 | 5,6-Diphenyl-1,2,4-Triazinic Dimeric Derivatives and the Use Thereof in the Form of Sun-Protective Agents - The invention relates to 5,6-diphenyl-1,2,4-triazinic compounds of general formula (I), wherein identical or different R1, R2, R3 and R4 represent a hydrogen, fluoride, chloride or bromine atom, C1 to C12 linear or branched alkyl, C1 A C18 linear or branched hydroxy, alkoxy poly(ethoxy)-alkoxy with a C1 to C4 alkyl fragment and an ethoxy number ranging from 1 to 4, amino or mono or di-alkylamino with a C1 to C4 alkyl fragment group, X is ortho-, meta- or paraphenylene, 4,4′-biphenylene, 2,4- or 2,6- or 3,4- or 3,5-pyridinylene, 2,2′-bipyridinylene, meta- or paraphenylenediamino, ethylenediamine, 2,2′-piperazinylene, diacyl of formula -(R4CO)2-, wherein r represents a phenyl radical, a 3 to 10 carbon, phenanthrene or anthracene atoms alkyl chain except 1,4-bis(5,6-diphenyl-1,2,4-triazin-3-yl)benzene of 2,4-bis(5,6-diphenyl-1,2,4-triazin-3-yl)pyridine and of 2,6-bis(5,6-diphenyl-1,2,4-triazin-3-yl)pyridine, to cosmetic compositions containing said compounds and to the use thereof in the form of sun filters or light-protective agents. | 2008-10-30 |
| 20080267893 | HYPERBRANCHED COPOLYMER COMPRISING MONOMERS OF CHOICE, A COMPOSITION, AND A COSMETIC METHOD - Disclosed is a hyperbranched copolymer comprising at least two polymeric branches, which may be identical or different, each comprising at least one at least trifunctional branch point, wherein a first polymeric branch comprises at least one first monomer chosen from isobornyl acrylate, isobornyl methacrylate, isobutyl acrylate, isobutyl methacrylate and 2-ethylhexyl acrylate, a second polymeric branch comprises at least one second monomer chose from isobornyl acrylate, isobornyl methacrylate, isobutyl acrylate, isobutyl methacrylate and 2-ethylhexyl acrylate. | 2008-10-30 |
| 20080267894 | Acerola Fruit-Derived Pectin and Its Application - The present invention relates to a pectin derived from an acerola fruit or a hydrolysate thereof, comprising a complex formed of Aceronidin, which is a novel polyphenol compound. The pectin of the present invention can be used as an active ingredient of an antioxidant or a skin-whitening agent. | 2008-10-30 |
| 20080267895 | Antiperspirant Compositions - An anhydrous antiperspirant composition comprising from 2 to 25% by weight of solubilised aluminium-containing antiperspirant active; from 20 to 50% by weight of ethanol and from 20 to 55% by weight of one or more solubiliser oils selected from the group consisting of: (i) a branched-chain fatty alcohol having from 16 to 24 carbon atoms; (ii) a benzoate ester of a short chain (C2-C6) alcohol substituted with a phenyl, phenoxy or benzoyloxy group; (iii) a benzoate ester of a straight-chain alcohol of from 6 to 8 carbon atoms; and (iv) a propoxylated linear fatty alcohol having a degree of propoxylation of from 2 to 4 and a fatty alcohol chain length of from 10 to 18 carbon atoms; wherein the ratio of antiperspirant active to ethanol and of antiperspirant active to the solubiliser oil is from 1:10 to 1:1 by weight and the ratio of ethanol to oil is from 1:2 to 2:1 by weight. | 2008-10-30 |
| 20080267896 | Cosmetic Compositions Comprising At Least One Bis-Urea Derivative - The present disclosure relates to cosmetic compositions comprising at least one continuous liquid fatty phase comprising at least one compound of formula (I), | 2008-10-30 |
| 20080267897 | Cosmetic compositions comprising at least one carboxylic anionic surfactant and at least one vinylamide/vinylamine copolymer, and processes of use thereof - Disclosed herein are cosmetic compositions comprising:
| 2008-10-30 |
| 20080267898 | Cosmetic or Personal Care Composition Comprising a Polymer Comprising Oxazolidon Groups - The invention relates to a cosmetic or personal care composition comprising a polymer which polymer comprises oxazolidon groups. Examples of cosmetic and personal care compositions include hair spray compositions, mousses, gels, lotions, tonics, shampoos, conditioners, rinses, hand and body lotions, facial moisturizers, sunscreens, anti-acne preparations, topical analgesics, mascara's, eyeliners, blush, liquid lip color, nail polish and foundations. | 2008-10-30 |
| 20080267899 | PLANT EXTRACT COMPOSITION FOR HAIR GROWTH - The present invention relates to a composition comprising a | 2008-10-30 |
| 20080267900 | Surface Treatment - The present invention relates to a method of treating solid surfaces where a suspendable liquid mist provided with suitable surfactants is applied to the surface to be treated, and the liquid mist drops have a surfactant content of from 10 to 3000 ppm by weight, based on the total amount of solvent, and an average drop size (weight-average) of ≦100 μm and to the use of surfactant-containing suspendable liquid mists for deodorization, decontamination, disinfection, corrosion protection, preservation, the stripping of solid surfaces or the placing of beneficial animals and microorganisms onto these. | 2008-10-30 |
| 20080267901 | Biocompatible Polymer Networks - Functionalized prepolymers and biocompatible polymer networks are disclosed, especially biodegradable polymer networks obtainable by polymerization of the functionalized prepolymers by for example ultraviolet (UV), redox, and/or heat radical polymerization. Functionalized prepolymers (macromers) are obtainable by reaction of a prepolymer comprising at least one alcohol, amine, and/or sulfhydril group, with an unsaturated mono-esterified dicarbonic acid, especially fumaric acid mono-ethyl ester. | 2008-10-30 |
| 20080267902 | BLOOD PRODUCTS WITH BINDING AGENT - The present invention provides a non-liquid biomaterial that may be used as a surgical sealant, a suture support, a blood flow controller, an adhesion reducing agent, an adhesion preventing agent, a tissue support, a tissue filler, a wound dressing or a combination thereof. The non-liquid biomaterial may comprise a blood derived material such as plasma, platelet poor plasma, platelet rich plasma or a material derived from blood containing tissue aspirate, such as bone marrow aspirate, a protein binding agent and a polymerizing agent. Methods for making and using the non-liquid biomaterial are also provided. | 2008-10-30 |
| 20080267903 | Bioactive Polymers - Various polymers, including cationic polyamine polymers and dendrimeric polymers, are shown to possess anti-proliferative activity, and may therefore be useful for treatment of disorders characterised by undesirable cellular proliferation such as neoplasms and tumours, inflammatory disorders (including autoimmune disorders), psoriasis and atherosclerosis. The polymers may be used alone as active agents, or as delivery vehicles for other therapeutic agents, such as drug molecules or nucleic acids for gene therapy. In such cases, the polymers' own intrinsic anti-tumour activity may complement the activity of the agent to be delivered. | 2008-10-30 |
| 20080267904 | Compositions Having A High Antiviral And Antibacterial Efficacy - Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The antimicrobial compositions contain a phenolic antimicrobial agent, a surfactant, a hydrotrope, a hydric solvent, and an organic acid, wherein the phenolic antimicrobial agent is present in a continuous aqueous phase in an amount of at least 25% of saturation concentration and the composition has a pH of about 5 or less. | 2008-10-30 |
| 20080267905 | Methods and Compositions Using Selective Cytokine Inhibitory Drugs for Treatment and Management of Cancers and Other Diseases - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of a selective cytokine inhibitory drug. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2008-10-30 |
| 20080267906 | Novel Spirotropane Compounds and Methods for the Modulation of Chemokine Receptor Activity - Compounds according to formula (I): | 2008-10-30 |
| 20080267907 | Stabilized Polypeptide Formulations - The present invention relates to a pharmaceutical formulation comprising a polypeptide and ethylenediamine or salts thereof and an antimicrobial preservative agent. | 2008-10-30 |
| 20080267908 | Il-32 Modulators - The present invention relates to methods of screening for modulators of interleukin 32 (IL-32), to modulators of IL-32 and to their use. Proteinase 3 has been identified as an IL-32 binding protein capable of deavege thereof. Inhibition of PR 3 activity to process IL-32 or neutralization of IL-32 by-inactive PR3 or its fragments may reduce the consequences of IL-32 in immune regulated diseases (e.g. inflammatory diseases). | 2008-10-30 |
| 20080267909 | PHAGOCYTE ENHANCEMENT THERAPY FOR ATHEROSCLEROSIS - Compounds that increase phagocytosis of apoptotic macrophages or necrotic cells that are associated with advanced atherosclerotic lesions are useful for treating atherosclerosis. Methods are provided for identifying such compounds and for preventing or treating atherosclerosis by increasing phagocytosis of apoptotic macrophages associated with advanced atherosclerotic lesions. | 2008-10-30 |
| 20080267910 | Rat, rabbit, and cynomolgus monkey IL-21 and IL-22 nucleotide and polypeptide sequences - This disclosure provides isolation and characterization of nucleotides encoding rat and cynomolgus monkey IL-21 and rat, rabbit and cynomolgus monkey IL-22, and the IL-21 and IL-22 polypeptides encoded thereby. This disclosure features rat and cynomolgus monkey IL-21 and rat, rabbit and cynomolgus monkey IL-22 nucleotide and amino acid sequences and variants thereof. | 2008-10-30 |
| 20080267911 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 2008-10-30 |
| 20080267912 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 2008-10-30 |
| 20080267913 | METHOD TO ENHANCE HEMATOPOIESIS - The present invention relates generally to the fields of immunology and molecular biology, and particularly to a method for treating hematopoietic disorders. The invention provides a method to treat a deficiency of one or more types of blood cells in a mammal, which includes administering an effective amount of TISF or of a compound that stimulates CD | 2008-10-30 |
| 20080267914 | Chemical Compounds - Compounds of formula (Ia) are found to be active in inhibiting replication of flaviviridae viruses (Ia), wherein R | 2008-10-30 |
| 20080267915 | Hcv Ns3-Ns4a Protease Inhibition - The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3-NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype-3. The methods of the invention emply inhibitors that act by interfering with the life cycle of the HCV and are also useful as antiviral agents. The invention further relates to compositions comprising such compounds either for ex vivo use or for administration to a patient suffering from genotype-2 or genotype-3 HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. | 2008-10-30 |
| 20080267916 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 2008-10-30 |
| 20080267917 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to functionalized amides of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. | 2008-10-30 |
| 20080267918 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 2008-10-30 |
| 20080267919 | ANGIOGENESIS-PROMOTING SUBSTRATE - An angiogenesis-promoting substrate which can be manufactured easily and in reproducible quality and which, in particular, under physiological conditions, remains stable for a specified time and yet is biocompatible and resorbable is provided, comprising a porous shaped body formed from a gelatin-containing material which is insoluble and resorbable under physiological conditions. | 2008-10-30 |
| 20080267920 | MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES - The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals. | 2008-10-30 |
| 20080267921 | Cardiac Stem Cells - Human cardiac stem cells can be isolated from endomyocardial biopsies. Such cells mediate cardiac regeneration and improve heart function in a mouse infarct model. The cells can be used for autologous, allogeneic, syngeneic, or xenogeneic therapeutic applications in patients. The stem cells can be genetically modified to enhance their therapeutic activity. | 2008-10-30 |
| 20080267922 | SLITRKS AS MARKERS FOR STEM AND PROGENITOR CELLS AND METHODS OF USE THEREOF - The present invention relates to slitrk proteins as markers of stem and progenitor cells, including embryonic stem cells and hematopoietic stem and progenitor cells, and also as a marker of leukemia and lymphoma cells, and of endothelial cells. The invention provides, inter alia, methods for purifying slitrk-positive cells, methods for detecting slitrk-positive cells, purified preparations of slitrk-positive cells, therapeutic compositions containing purified slitrk-positive cells, methods for targeting therapeutic agents to slitrk-positive cells, and methods of treatment, including but not limited to, methods of administering slitrk-positive cells to subjects in need thereof. | 2008-10-30 |
| 20080267923 | HAIR UNDIFFERENTIATED CELLS - An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or direct surgical placement/implantation of autologous cultured cells and/or cultured cell-produced extracellular matrix that is derived from connective tissue, dermis, fascia, lamina propria, stroma, adipose tissue, muscle, tendon, ligament or the hair follicle. The corrective application is done on tissue proximal or within the area of the defect. The method involves retrieving viable cells from the subject, a neonate or human fetus. Alternatively, the corrective application involves the cells placed in a matrix, preferably comprised of autologous extracellular matrix constituents as a three-dimensional structure or as a suspension, prior to placement into a position with respect to the subject's defect. In a further embodiment, the preferable autologous extracellular matrix constituents are collected from culture and placed in a position with respect to the subject's defect. | 2008-10-30 |
| 20080267924 | AUTOLOGOUS LYMPH NODE TRANSFER IN COMBINATION WITH VEGF-C OR VEGF-D GROWTH FACTOR THERAPY TO TREAT SECONDARY LYMPHEDEMA AND TO IMPROVE RECONSTRUCTIVE SURGERY - The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery. | 2008-10-30 |
| 20080267925 | Cell Therapy: A Method And A Composition For Treating Diabetes - A method of obtaining beta-islet cells from pancreases of rabbits and a composition for transplantation (xenografts or xenotransplants) of beta-islet cells isolated and cultured from rabbit pancreases to promote natural insulin production among people with diabetes. | 2008-10-30 |
| 20080267926 | METHODS OF PRODUCING PANCREATIC HORMONES - Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy. | 2008-10-30 |
| 20080267927 | Methods for improving cell therapy and tissue regeneration in patients with cardiovascular diseases by means of shockwaves - Improving cell therapy and tissue regeneration in a patient suffering from a cardiovascular or a neurological disease by treating a tissue of the patient with shock waves and/or applying to the patient a therapeutically effective amount of stem cells and/or progenitor cells. Such treatment increases expression of chemoattractants, pro-angiogenic factors, and pro-survival factors. The chemoattractants can be, for example, vascular endothelial growth factor (VEGF) or stromal cell derived factor 1 (SDF-1). For example, the treated tissue can be located in the patient's heart or in a skeletal muscle of the patient, and the shock waves can be extracorporeal shock waves (ESW) or intracorporeal shock waves. The cardiovascular disease can have an ischemic or non-ischemic etiology. For example, the cardiovascular disease can be a myocardial infarction, ischemic cardiomyopathy, or a dilatative cardiomyopathy. For example, the neurological disease can be a peripheral neuropathy or neuropathic pain. | 2008-10-30 |
| 20080267928 | Compositions and Methods for Making Insulin-Producing Cells - An insulin-producing cell made by delivering a combination of at least two transcription factors, such as Pdx-1 and Pax4, to a liver cell. Cells according to the invention can be used to reduce an insulin insufficiency in a diabetic subject. | 2008-10-30 |
| 20080267929 | Use of stem cells to generate inner ear cells - This invention relates generally to methods and compositions for inducing stem cell or progenitor cell differentiation, and more particularly to methods and compositions for inducing differentiation of stem cells and/or progenitor cells into cells that function within the inner ear. | 2008-10-30 |
| 20080267930 | Biological Materials and Uses Thereof - A method of producing a reprogrammed cell or reprogrammed cell nucleus, comprising exposing a differentiated cell, or the nucleus of a differentiated cell to a cell or cell extract thereof derived from an oocyte, egg, ovary or early embryo of a cold blooded vertebrate, wherein the cold blooded vertebrate has one or more of the following properties: (i) a primitive vertebrate body plan including laterally projecting ribs and/or spinal projections; (ii) germ cells which do not contain germ plasm; and/or (iii) the oocyte, egg, ovary or early embryo cell or cell from which the cell extract is derived, expresses a highly conserved form of Oct-4 and/or nanog. There is also provided uses of the reprogrammed cells. | 2008-10-30 |
| 20080267931 | Compositions for Silencing the Expression of Vdac1 and Uses Thereof - The present invention relates generally to the down regulation of mitochondrial protein, voltage-dependent anion channel (VDAC1), expression by RNAi or antisense therapy. In particular, the present invention is directed to VDAC1 silencing molecules useful in regulating cell proliferation and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with aberrant cell proliferation. | 2008-10-30 |
| 20080267932 | Lactobacillus Rhamnosus with Body-Fat Reducing Activity and the Foods Containing Them - The present invention relates to | 2008-10-30 |
| 20080267933 | Probiotics to Influence Fat Metabolism and Obesity - Use of probiotic bacteria for the manufacture of a food product, feed product, dietary supplement, nutritional product, natural remedy, pharmaceutical active formulation and medicinal product to be used for controlling weight gain, preventing obesity, increasing satiety, prolonging satiation, reducing food intake, reducing fat deposition, improving energy metabolism, enhancing insulin sensitivity, treating obesity and treating insulin insensitivity. The probiotic bacteria is at least one of | 2008-10-30 |
| 20080267934 | Use of Apoptotic Cells Ex Vivo to Generate Regulatory T Cells - Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004). | 2008-10-30 |
| 20080267935 | AraC in combination with a cytokine-secreting cell and methods of use thereof - The present invention provides improved method of cancer therapy in a mammal. More particularly, the invention is concerned with systems comprising cytosine arabinoside (AraC) and a cytokine-expressing cancer immunotherapy composition and methods of administering the combination to cancer patients in order to generate an immune response against the cancer and provide treatment with therapeutic efficacy that is an improvement relative to administration of AraC or the cytokine-expressing cancer immunotherapy composition alone as a monotherapy. | 2008-10-30 |
| 20080267936 | Treatment of trauma-hemorrhage with short oligopeptides - Described are methods and associated means for treating a subject, such as a mammal, experiencing or thought to be at risk for hemorrhagic shock. Such methods include administering to the subject in a medically acceptable manner, a short oligopeptide such as AQGV (SEQ ID NO:1) and/or LQGV (SEQ ID NO:2). | 2008-10-30 |
| 20080267937 | Compositions for Preventing Plant Disease Comprising Bacillus Subtilis Kccm 10639 or Kccm 10640 and Methods of Preventing Plant Disease by Using Them - The present invention relates to a composition for controlling plant diseases, which comprises novel bacterial strain | 2008-10-30 |
| 20080267938 | CARDIAC PHYTO-NUTRACEUTICAL SYNERGISTIC COMPOSITION - A Phytoceutical composition for the prevention and treatment of cardiac affections is provided. A specific combination of extracts of plants and nutraceuticals is provided, based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combinations have synergistic effects, with minimal side effects. | 2008-10-30 |
| 20080267939 | SYNERGISTIC ANTI-HYPERTENSIVE PHYTO-NUTRACEUTICAL COMPOSITION - A Phyto-nutraceutical composition for the prevention and treatment of hypertensive disorders is provided. A specific combination of extracts of plants and nutraceuticals is provided, based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combinations have synergistic effects, with minimal side effect. | 2008-10-30 |
| 20080267940 | Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue - The present invention is drawn to concentrated fibrinogen compositions and associate methods and use thereof. The concentrated fibrinogen compositions can be produced by adding a sufficient amount of a cationic agent, such as protamine, to a fibrinogen containing fluid to cause the fibrinogen to form a fibrinogen precipitate; collecting the fibrinogen precipitate by a collection means, such as centrifugation; and suspending or solubilizing the fibrinogen precipitate in a liquid vehicle to form a concentrated fibrinogen composition. The concentrated fibrinogen compositions can be incorporated into systems for making fibrin glues and be used in treating wounds. | 2008-10-30 |
